Zoetis CFO Awarded Phantom Stock Units Valued at $10.7K
Zoetis Inc.
Subscribe to track ZTS
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Zoetis CFO Awarded Phantom Stock Units Valued at $10.7K
Company: Zoetis Inc. (ZTS) Form: 4 | Filed: 2025-10-14 Significance: Low
Insider: Joseph Wetteny Title: Chief Financial Officer | Relationship: Officer
Transaction: • Type: Award • Shares: 230.5564 • Price: $46.71 • Value: $10,769.20 • Owned After: 6,585.9941
Key Insight: This is a routine award of phantom stock units to the CFO as part of a supplemental savings plan. It is not an open market transaction and has low signaling value.
Market Context: The transaction is part of a standard compensation structure and does not indicate a change in the executive's outlook on the company's performance.
This is PUBLIC SEC data for educational purposes. Not investment advice.
Comprehensive Analysis
SEC Filing Analysis: Zoetis Inc. (ZTS)
Executive Summary
- Trading Significance: Low
- Key Takeaway: The Chief Financial Officer of Zoetis Inc. received a routine award of phantom stock units valued at approximately $10,769 as part of a company savings plan. This is a compensatory transaction, not an open-market trade, and carries minimal predictive value for the stock's future performance.
- Market Impact: The market impact is expected to be neutral. Such routine compensation-related filings are common and typically do not influence investor sentiment or trading volume.
Company Information
| Field | Value |
|---|---|
| Company | Zoetis Inc. |
| Ticker Symbol | ZTS |
| CIK | 0001555280 |
| Industry | PHARMACEUTICAL PREPARATIONS [2834] |
Insider Information
| Field | Value |
|---|---|
| Name | Joseph Wetteny |
| CIK | 0001285781 |
| Title/Position | Chief Financial Officer |
| Relationship | Officer |
Transaction Details
| Field | Value |
|---|---|
| Form Type | 4 |
| Transaction Date | 2025-10-10 |
| Transaction Code | A (Award) |
| Security Type | Phantom Stock Unit |
| Shares Involved | 230.5564 |
| Price Per Share | $46.71 |
| Total Value | $10,769.20 |
| Shares Owned After | 6585.9941 |
| Ownership Type | Direct |
Market Impact Analysis
Stock Impact Prediction
- Direction: Neutral
- Reasoning: The transaction is an award (Code 'A'), which is part of an executive's compensation package. It does not represent a discretionary investment decision by the insider based on their view of the company's future. The value of the transaction is also nominal for a CFO of a large-cap company.
Volume & Sentiment
- Expected Volume Impact: Negligible. The market does not typically react to small, routine compensation awards.
- Sentiment Indicator: Neutral. This filing provides no bullish or bearish signal as it is not an open-market purchase or sale.
Investment Insights
Positive Market Indicators
- N/A. This transaction does not provide positive market indicators.
Risk Factors
- N/A. This transaction does not introduce new risk factors.
Key Takeaways
- Routine Compensation: The acquisition of phantom stock units is part of the Zoetis Supplemental Savings Plan, a standard compensation mechanism.
- Not an Open-Market Trade: This is not a purchase of shares on the open market, which would be a stronger signal of insider confidence.
- Low Signaling Value: Due to the nature (award) and small size of the transaction, it holds little to no significance for investment analysis.
Contextual Analysis
Timing Significance
- The transaction date and filing are routine and do not coincide with any major market-moving news, suggesting it is part of a regular compensation schedule.
Transaction Context
- According to Footnote 1, the phantom stock units were acquired via the Zoetis Supplemental Savings Plan and are settled in cash upon separation from service. This confirms the compensatory nature of the transaction.
- Footnote 2 clarifies that each unit's value is tied to Zoetis common stock and a small cash-equivalent component.
Company Context
- Zoetis is a leading global animal health company. This filing represents business-as-usual for executive compensation within the firm and does not reflect any specific operational or strategic shifts.
Risk Assessment
Risk Level: Low
Risk Factors
- This specific filing presents no discernible risks to investors.
Market Considerations
- Investors should differentiate between compensatory awards (like this one) and discretionary open-market trades when analyzing insider activity.
- The focus for Zoetis should remain on fundamental business performance, industry trends in animal health, and competitive positioning, rather than on minor insider filings of this nature.
IMPORTANT DISCLAIMER: This analysis is for informational purposes only and is not intended as investment advice. The information presented is based on publicly available SEC filings and should not be construed as a recommendation to buy, sell, or hold any securities. Past performance does not guarantee future results. All investments carry risk, including the potential loss of principal. Please consult with a qualified financial advisor before making any investment decisions.
Analysis generated on 2025-10-14 | Data source: SEC EDGAR
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.